Does DASATINIB Cause Second primary malignancy? 37 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Second primary malignancy have been filed in association with DASATINIB (dasatinib). This represents 0.1% of all adverse event reports for DASATINIB.
37
Reports of Second primary malignancy with DASATINIB
0.1%
of all DASATINIB reports
8
Deaths
7
Hospitalizations
How Dangerous Is Second primary malignancy From DASATINIB?
Of the 37 reports, 8 (21.6%) resulted in death, 7 (18.9%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DASATINIB. However, 37 reports have been filed with the FAERS database.
What Other Side Effects Does DASATINIB Cause?
Pleural effusion (2,424)
Fatigue (2,173)
Death (1,741)
Nausea (1,740)
Diarrhoea (1,728)
Headache (1,625)
Adverse event (1,382)
Rash (1,300)
Drug ineffective (1,271)
Hospitalisation (1,181)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which DASATINIB Alternatives Have Lower Second primary malignancy Risk?
DASATINIB vs DATOPOTAMAB DERUXTECAN-DLNK
DASATINIB vs DAUNORUBICIN
DASATINIB vs DAXIBOTULINUMTOXIN A-LANM
DASATINIB vs DAYTRANA
DASATINIB vs DECITABINE